MichaelR.SnellMD

Oncology • Richmond, IN

Assistant Professor, Medicine, Case Western Reserve University School of Medicine

Join to view full profile

Dr. Snell is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Snell's full profile

Already have an account?

Office
1100 Reid Pkwy
Richmond, IN 47374
Phone+1 216-778-7800
Is this information wrong?

Education & Training

Case Western Reserve University/University Hospitals Cleveland Medical CenterFellowship, Hematology and Medical Oncology, 2004 - 2007
Case Western Reserve University School of MedicineClass of 2002

Certifications & Licensure

HI State Medical License 2022 - 2026
OH State Medical License 2001 - 2026
CA State Medical License 2018 - 2024
IN State Medical License 2017 - 2019
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

20 citations
Randomized Phase II Trial of Erlotinib Beyond Progression in Advanced Erlotinib-Responsive Non-Small Cell Lung Cancer
Balazs Halmos, Nathan A. Pennell, Pingfu Fu, Shumaila Saad, Shirish M. Gadgeel, Gregory A. Otterson, Tarek Mekhail, Michael R. Snell, J. Philip Kuebler, Neelesh Sharma...> ;The Oncologist. 2015 Nov 1
Erlotinib beyond progression study: Randomized phase II study comparing chemotherapy plus erlotinib with chemotherapy alone in EGFR TKI-responsive, advanced non-small ...
Halmos B, Fu P, Pennell NA, Otterson GA, Mekhail T, Snell MR, Kuebler JP, Gadgeel SM, Conrad A, Stefanski AT, Dowlati A> ;J. Clin. Oncol.. 2011-05-20
14 citations
Targeting base excision repair suggests a new therapeutic strategy of fludarabine for the treatment of chronic lymphocytic leukemia.
A. D. Bulgar, Michael Snell, Jon R. Donze, E. B. Kirkland, L. Li, Sichun Yang, Yan Xu, Stanton L. Gerson, Lili Liu> ;Leukemia. 2010 Sep 2
18 citations
Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma.
Paul M. Barr, Pingfu Fu, Hillard M. Lazarus, Nancy Horvath, Stanton L. Gerson, Omer N. Koc, Nizar J. Bahlis, Michael R. Snell, Afshin Dowlati, Brenda W. Cooper> ;British Journal of Haematology. 2009 Oct 1
73 citations
Thrombotic microangiopathy in haematopoietic stem cell transplantation: diagnosis and treatment.
Cecilia M. Choi, Alvin H. Schmaier, Michael Snell, Hillard M. Lazarus> ;Drugs. 2009 Jan 1
Phase II trial of becatecarin (rebeccamycin analogue) in relapsed sensitive small cell lung cancer (SCLC).
Dowlati A, Mekhail T, O'Brien T, Rutherford K, Snell M, Ness A, Ma P, Ivy SP, Halmos B> ;J. Clin. Oncol.. 2008-05-20
14 citations
Lack of isohemagglutinin production following minor ABO incompatible unrelated HLA mismatched umbilical cord blood transplantation.
Michael Snell, C. Chau, D. Hendrix, R. M. Fox, Katharine A. Downes, Richard J. Creger, Howard J. Meyerson, Marilyn J. Telen, Mary J. Laughlin, Hillard M. Lazarus, Rosl...> ;Bone Marrow Transplantation. 2006 Jun 5
Join now to see all

Press Mentions

Michael Snell M.D., Joins the Oncology Institute of Hope and InnovationJune 26th, 2019

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

Hospital Affiliations

Providence St. Joseph Hospital EurekaEureka, California
Maui Memorial Medical CenterWailuku, Hawaii